retatrutide compared to tirzepatide vs Retatrutide vs Tirzepatide: 28.7% vs

Tirzepatide: dual-pathway incretin research compound with broad vial-size coverage

*Correspondence: Juergen Eckel, Paul-Langerhans-Group for Integrative Physiology, German Diabetes Center, Aufm Hennekamp 65, Dsseldorf D-40225, Germany, [email protected] Specialty section: This article was submitted to Chemoattractants, a section of the journal Frontiers in Immunology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

10.1016/j.cmet.2006.02.004 317

Every coverage decision runs through a set of filters

This makes deployment incompatible with active dosing in many cases